Zai Lab vs Zymeworks
ZLAB and ZYME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ZLAB and ZYME compare
Zai Lab is the larger company, worth 20 times as much as Zymeworks ($41.0B against $2.1B).
Zymeworks grew revenue faster over the last twelve months (97.8% versus 0.02% for Zai Lab).
Zymeworks keeps more of each dollar of sales as profit, with a net margin of 16.3% compared with −44.9% at Zai Lab.
Zymeworks scores higher on the StockData Score (10 against 6 for Zai Lab), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ZLAB | ZYME |
|---|---|---|
| Size and price | ||
| Market cap | $41.0B | $2.1B |
| Share price | $26.42 | $29.07 |
| Change, 1 year | 20.7% | 61.1% |
| Change, 5 years | −68.6% | 46.7% |
| Beta (5Y) | 1.11 | 0.84 |
| Employees | 1,784 | 264 |
| StockData Score | ||
| Total score | 6 | 10 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 3 | 4 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 55.9× |
| P/S | 92.9× | 7.8× (better) |
| P/B | 72.8× | 8.0× (better) |
| EV/EBITDA | – | 44.4× |
| FCF yield | −0.40% (better) | −5.5% |
| Fair value | $4.31 | $12.06 |
| Margin of safety | −513% | −141% (better) |
| Growth | ||
| Revenue growth (TTM) | 0.02% | 97.8% (better) |
| Revenue growth, 5Y average | 56.5% (better) | 22.2% |
| Profitability | ||
| Gross margin | 54.7% | – |
| Operating margin | −63.0% | 16.6% (better) |
| Net margin | −44.9% | 16.3% (better) |
| FCF margin | −37.0% (better) | −42.4% |
| Return on equity | −30.0% | 15.0% (better) |
| Return on invested capital | −87.6% | 21.4% (better) |
| Financial health | ||
| Debt / equity | 0.45 (better) | 0.00 |
| Interest coverage | −45.2× | – |
| Current ratio | 2.04 | 3.30 (better) |
| Altman Z-score | 49.70 (better) | 0.87 |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 8.0% |
| Shareholder yield | 0.00% | 8.0% (better) |
| Ownership | ||
| Held by institutions | 2.8% | 98.1% |
| Held by insiders | 0.67% | 58.9% |
| Insider net buying, 12 months | −$10.8M | −$5.0M (better) |
| Short interest, % of float | – | 20.3% |
Go deeper
- ZLAB stock overview
- ZLAB income statement
- ZLAB valuation and score
- ZYME stock overview
- ZYME income statement
- ZYME valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.